Dr. Paul Hallenbeck to Present at Oncolytic Virotherapy Summit 2023
11 Dec 2023 //
BUSINESSWIRE
Dr. Paul Hallenbeck, CSO of Seneca to Present at World Vaccine Congress
27 Nov 2023 //
BUSINESSWIRE
Seneca Therapeutics Announces Publication of TEM8 Review Article
15 Nov 2023 //
BUSINESSWIRE
Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors
05 Jun 2023 //
BUSINESSWIRE
Seneca Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study
03 Oct 2022 //
BUSINESSWIRE
Industry Veteran Cuong Do Joins Seneca Therapeutics, Inc. Advisory Board
31 May 2022 //
BUSINESSWIRE
Seneca Tx to Present at the World Vaccine Congress in Washington, DC
18 Apr 2022 //
BUSINESSWIRE
Seneca Tx Presents Promising Data of SVV-001 with Checkpoint Inhibitors at AACR
11 Apr 2022 //
BUSINESSWIRE